Latest news
Alzheimer’s Treatment Moves Home. Risk Does Not.
FDA approval of Leqembi Iqlik as a subcutaneous initiation dose could reduce infusion burden in early Alzheimer’s disease. But moving treatment closer to home does not make anti-amyloid care simple.
MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.
A Boot-Camp Flu Outbreak Put Pentagon Vaccine Policy to the Test.
England Moved the Vaccine Clock. The Coverage Gap Stayed Put
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
IPM Brief – Issue 7 | The Gate Is the Product
AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.
MS Does Not End at the Clinic Door. It Follows People Into Work, Money and Relationships.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.